Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients

  • Kim, Haeyoung (Department of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital) ;
  • Choi, Doo Ho (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Seok Jin (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jeong Eon (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn, Jin Seok (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Im, Young-Hyuck (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2013.09.17
  • Accepted : 2013.11.19
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study was performed to evaluate prognostic factors for survival from first relapse (SFFR) in stage I-III breast cancer patients. Materials and Methods: From June 1994 to June 2008, 3,835 patients were treated with surgery plus postoperative radiotherapy and adjuvant chemotherapy for stage I-III breast cancer at Samsung Medical Center. Among them, a total of 224 patients died by June 2009, and 175 deaths were of breast cancer. Retrospective review was performed on medical records of 165 patients who met the inclusion criteria of this study. Univariate and multivariate analysis were done on survivals according to variables, such as age, stage, hormone status of tumor, disease-free interval (DFI), sites of first failure, number of organs involved by recurrent disease (NOR), application of salvage treatments, and existence of brain or liver metastasis (visceral metastasis). Results: Patients' median overall survival time was 38 months (range, 8 to 123 months). Median SFFR was 17 months (range, 5 to 87 months). Ninety percent of deaths occurred within 40 months after first recurrence. The patients with SFFR ${\leq}1$ year had tendency of triple-negativity, shorter DFI (${\leq}2$ years), larger NOR (>3), visceral metastasis for first relapse than the patients with SFFR >1 year. In multivariate analysis, longer DFI (>2 vs. ${\leq}2$ years), absence of visceral metastasis, and application of salvage treatments were statistically significant prognosticators for longer SFFR. Conclusion: The DFI, application of salvage treatments, and visceral metastasis were significant prognostic factors for SFFR in breast cancer patients.

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
  3. Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat 2011;128:827-35. https://doi.org/10.1007/s10549-011-1366-9
  4. Lundin J, Lundin M, Isola J, Joensuu H. A web-based system for individualised survival estimation in breast cancer. BMJ 2003;326:29. https://doi.org/10.1136/bmj.326.7379.29
  5. Pirovano M, Maltoni M, Nanni 0, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manag 1999;17:231-9. https://doi.org/10.1016/S0885-3924(98)00145-6
  6. Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 1999;7:128-33. https://doi.org/10.1007/s005200050242
  7. Yun YH, Heo DS, Heo BY, Yoo TW, Bae JM, Ahn SH. Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep 2001;8:795-800.
  8. Chuang RB, Hu WY, Chiu TY, Chen CY. Prediction of survival in terminal cancer patients in Taiwan: constructing a prognostic scale. J Pain Symptom Manag 2004;28:115-22. https://doi.org/10.1016/j.jpainsymman.2003.11.008
  9. Bruera E, Miller MJ, Kuehn N, MacEachern T. Hanson J. Estimate of survival of patients admitted to a palliative care unit: a prospective study. J Pain Symptom Manag 1992;7:82-6. https://doi.org/10.1016/0885-3924(92)90118-2
  10. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence : relative importance of prognostic factors in 1,015 breast cancer patients. J Clin OncoI 1987;5:55-61. https://doi.org/10.1200/JCO.1987.5.1.55
  11. Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J. Survival after first recurrence of breast cancer: the Miami experience. Cancer 1992;70:129-35. https://doi.org/10.1002/1097-0142(19920701)70:1<129::AID-CNCR2820700122>3.0.CO;2-Y
  12. Robertson JF, Dixon AR, Nicholson RI, Ellis 10, Elston CW, Blamey RW. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 1992;22:221-7. https://doi.org/10.1007/BF01840835
  13. Harris JR, Hellman S. Observations on survival curve analysis with particular reference to breast cancert reatment. Cancer 1986;57:925-8. https://doi.org/10.1002/1097-0142(19860301)57:5<925::AID-CNCR2820570508>3.0.CO;2-L
  14. Shigematsu H, Kawaguchi H, Nakamura Y, et al. Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer 2011;11:118. https://doi.org/10.1186/1471-2407-11-118
  15. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-53. https://doi.org/10.1002/cncr.11083
  16. Puente J, Lopez-Tarruella S, Ruiz A, et al. Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Res Treat 2010;122: 591-600. https://doi.org/10.1007/s10549-009-0687-4
  17. Mauri D, Polyzos NP, Salanti G, Pavlidis N, loannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 2008;100:1780-91 . https://doi.org/10.1093/jnci/djn414
  18. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9. https://doi.org/10.1002/cncr.22867
  19. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010;19:312-21. https://doi.org/10.1016/j.breast.2010.03.026
  20. Liedtke C, Mazouni C. Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol 2008;26:1275-81. https://doi.org/10.1200/JCO.2007.14.4147
  21. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429-34. https://doi.org/10.1158/1078-0432.CCR-06-3045

Cited by

  1. Analysis of Indoleamine 2-3 Dioxygenase (IDO) and EGFR Co-expression in Breast Cancer Tissue by Immunohistochemistry vol.15, pp.14, 2013, https://doi.org/10.7314/apjcp.2014.15.14.5535
  2. Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC St vol.11, pp.5, 2013, https://doi.org/10.1371/journal.pone.0156221
  3. Lifetime cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for early stage breast cancer vol.15, pp.None, 2013, https://doi.org/10.1186/s12962-017-0084-5
  4. Diagnostic and prognostic value of 18 F-FDG PET/CT imaging in suspected recurrence of male breast cancer vol.40, pp.1, 2013, https://doi.org/10.1097/mnm.0000000000000928
  5. Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer vol.8, pp.5, 2013, https://doi.org/10.2217/cer-2018-0137
  6. Cancer recurrence times from a branching process model vol.15, pp.11, 2013, https://doi.org/10.1371/journal.pcbi.1007423
  7. Prognostic value of peptidyl-prolyl cis-trans isomerase 1 (PIN1) in human malignant tumors vol.22, pp.7, 2013, https://doi.org/10.1007/s12094-019-02233-5
  8. Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital vol.10, pp.10, 2013, https://doi.org/10.1136/bmjopen-2020-038798
  9. Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters vol.10, pp.None, 2013, https://doi.org/10.1038/s41598-020-64564-6
  10. The Risk of Antihypertensive Drug among Breast Cancer Patient: A Systematic Review and Meta-analysis vol.9, pp.6, 2021, https://doi.org/10.3889/oamjms.2021.6841